List of Personalized Medicine Companies in California - 68

Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company developing precision therapies for genetically-defined cancers.

Since its inception in 2013, AccuraGen has pioneered the development of liquid biopsy technology to facilitate more personalized cancer treatment. Our international team of scientists brings together the best of industry with the best of academia. We currently operate from two locations: Menlo Park, California and Shanghai, China.

We’re leveraging advances in genetics and precision medicine to develop new therapeutics that target shared, underlying biology in rare and common diseases — bringing meaningful medicines from one to many. With expertise in genetics, drug discovery and data sciences, we seek to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics for patients.

Aegea Biotechnologies, Inc. is a technology company that is developing a series of reagents, research kits and in-vitro diagnostic (IVD) products for molecular analysis based on novel, patented and proprietary nucleic acid chemistries and methodologies.

Agena Bioscience® empowers research laboratories worldwide to deliver scalable targeted genomic data. Our advanced platforms deliver timely molecular insights in the areas of mutation profiling, liquid biopsy, pharmacogenetics, and more. Agena offers the MassARRAY® System, an open platform that provides researchers with insights through a highly multiplexed solution. Headquartered in San Diego, with offices located around the world, Agena Bioscience fosters a highly collaborative culture for both our customers and employees, encouraging diversity, creativity, and most importantly, innovation.

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free. Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com. For view our social media policies, please visit https://agendia.com/legal-compliance/

Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. The NULISAseq Inflammation Panel contains 200+ important markers related to immune and inflammatory diseases and will run on our ARGO™ System. This innovative platform allows for a fully automated workflow with less than 30 minutes hands on time from sample to data.

AltheaDx, Inc. is a commercial stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx). IDgenetix® is AltheaDx’s PGx product test for depression and anxiety and is supported by a published/peer-reviewed Randomized Controlled Trial that demonstrated clinical utility over standard of care when physicians used the test prior to prescribing a medication.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with OntoChem GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.

Antigen Discovery, Inc. (formerly ImmPORT Therapeutics, Inc.) provides research services and products specializing in high throughput protein microarray technology that simplifies proteomic biomarker discovery and enables serological and immune profiling of whole proteomes.

We now know that immune cells – not only in the body’s periphery but especially in the brain – can produce autoantibodies that cause severe neurological and psychiatric diseases. Founded to explore the latest discoveries in autoimmune neuropsychiatry, Arialys Therapeutics is developing new precision medicines to specifically block pathogenic autoantibodies in the brain and meaningfully expand the treatment possibilities for neuropsychiatric disorders driven by autoimmune disease.

Harnessing the power of RNA biology to find treatments for patients with unmet medical needs. Advance and utilize the cutting edge antisense technology (siRNA and ASO) to discover and develop next generation medicines for both large and rare disease indications.

We are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. BioCardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its CardiAMP™ and CardiALLO™ therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. These programs are enabled by the Company's Helix™ transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.

BioChain is the world leader in high quality processed bio-sample products and analysis services used in advancing translational medicine, companion diagnostics, and clinical product research and development. BioChain's products are available for DNA and RNA sequencing, PCR and RT-PCR, gene expression analysis, DNA and RNA purification, protein extraction and purification, protein expression analysis, and liquid biopsy studies. BioChain's One-Stop Services for Next Generation Sequencing (NGS), from clinical sample collection, sample preparation, sequencing to bioinformatics analysis, will revolutionize the industry. In addition to our world-class bio-specimen and sample preparation line of business, BioChain is moving into the clinical applications that offer clinical genomics diagnostics products and clinical trial services in cancer and reproductive health. BioChain is committed to achieving the Highest Quality products and services at highly competitive prices through our Continuous Process Improvement Initiatives. BioChain established a comprehensive quality assurance program to meet our customers' satisfactions as well as maintaining both ISO 9001:2016 and ISO 13485:2016 certifications for our in house production facilities. Innovation and Collaboration: As an industry leader, BioChain is always striving to innovate and collaborate with the world's leading Pharmaceutical, Bio Technology, and Health Care organizations. We have a strong in-house scientific team and actively seek research and business partnerships with industry innovators and leaders.

Biolinq has created a new Biowearable experience by using an array of electrochemical sensors so small you can barely feel them. Our metabolic health sensors work together to provide maximum reliability for continuous sensing applications. With the potential of multiple analytes such as glucose, ketones, and lactate, we provide an entirely new user experience with actionable metabolic health insights. Over the next 10 years we intend to bring Biosensing and Biowearables mainstream. We are dedicated to the personal and professional growth of all our team members and strive to create a positive and creative work environment.

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. Our mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. We offer OGM solutions for applications across basic, translational and clinical research. Bionano also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through our Bionano Laboratories business, wey also offer OGM-based diagnostic testing services.

• The Cedars-Sinai Biomanufacturing Center (CBC) is a new 25,000 square feet, state-of-the-art biomanufacturing facility located in West Hollywood, California. • Manufacturing the next generation of cell and gene therapies for human IND-enabling clinical trials. • cGMP cell manufacturing facility housing multiple cleanroom cell production suites and process development laboratories. • Combined expertise in a cGMP-compliant approach to manufacture cells at scale with innovative technologies and equipment. • Transferring laboratory protocols to cGMP, up-scaling of processes and achieving Food and Drug Administration standards to bring innovative cell therapy solutions to researchers and translational scientists. • World-class expertise in stem cell (iPSC) biology, gene editing and bioprocessing. • Supporting California Institute for Regenerative Medicine (CIRMN) programs, CBC is providing a much-needed cell biomanufacturing center in California

We're a dedicated team of engineers, data scientists, doctors, innovators, and creative thinkers from across the globe. We're united in our drive to use technology to simplify healthcare and make it work better for everyone involved. We unify all data sources and other systems together for a complete picture. We automate for efficiency throughout. Clinical, operations, and financial results are collected and coordinated like never before.

Sutter Health is one of the nation's leading not-for-profit healthcare systems, which includes award-winning physician organizations, acute care hospitals, surgery centers, medical research facilities and specialty services. Our team of 68,000 doctors, employees and volunteers proudly cares for Northern California. Our facilities and care centers are located in large, urban cities and small, rural communities, from the Pacific Coast to the San Joaquin Valley. You'll find us in San Francisco, Oakland, Sacramento, the snowy mountains of the Sierra Nevada and Lake Tahoe, Napa Valley, Yosemite and the coastal redwoods. We even have an affiliate in Hawaii. Join us and be part of a dedicated group of professionals committed to putting patients' needs first and achieving the highest levels of quality, access and affordability.

Cureline is a global precision and translational medicine CRO located in California (USA). With more than a hundred validated clinical partners in 20 countries, HBS repository in San Francisco Bay area and excellence in laboratory services, Cureline provides a full spectrum of translational research services: global regulatory affairs, custom protocol HBS biobanking, histopathology & digital pathology, molecular and cellular lab services, small animal studies and cell and gene therapy (ATMP) solutions. Since 2003 Cureline is a global leader in commercial biobanking and biomedical research services with a focus on targeted drug R&D, biomarker research and companion diagnostics development.

CureMatch is a leader in AI-based precision medicine, digital decision support solutions that support cancer treatment. Created to empower oncologists with world-class research and sophisticated AI algorithms, the CureMatch Decision Support System assists the doctor with understanding therapeutic options that are personalized to the unique molecular profile of the individual patient's tumor.

Develop artificial intelligence that is utilized to aid and augment certified genetic counselors and pharmacists, during pre-test, post-test and support services.

Encoded Therapeutics is creating one-time, disease-modifying gene therapies for pediatric central nervous system (CNS) disorders with its cell-selective targeting and regulation platform. The Encoded approach offers potentially unprecedented gene specificity and cell selectivity to unlock novel opportunities by targeting a range of disease mechanisms. Encoded’s technology is compatible with any delivery system to control where and when therapeutic transgenes are expressed, thereby shaping the functionality of target cells and holding broader therapeutic potential beyond CNS disorders.

Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor’s lead investigational candidate, ENV-101, is an inhibitor of the Hedgehog (Hh) signaling pathway in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The company’s second investigational candidate, ENV-501 is a human epidermal growth factor 3 (HER3)-targeted antibody-drug conjugate (ADC) for the treatment of HER3-positive solid tumors.

At Exact Sciences, our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. We're hiring! Our organization offers something for everyone, at all stages of careers and from all backgrounds. Let's take on cancer, together.

Exagen Inc. is a Patient Focused, Discovery Driven, CLIA-certified, CAP-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of Rheumatology and Autoimmune diseases. Committed to Personalized Medicine, our AVISE tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management.

Exceltox is a CAP-accredited, CLIA-certified laboratory offering advanced clinical, pharmacogenomic,and toxicology testing.

GATC Health Corp is a technology company revolutionizing drug discovery and development through its transformative AI platform and approach, which accelerates therapeutic development with accuracy, efficiency and speed never before achieved in medical science. The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) platform simulates human biochemistry’s billions of interactions for accurate and rapid novel target identification/verification, and drug discovery/development. GATC Health envisions the future of medicine now, where disease is reversed safely so everone can live their best lives.

Our mission is to enable a world where everyone's health is informed by genetics. As a leading telegenetics care delivery company, we make genetics care accessible and actionable for patients throughout the U.S. and Canada through seven-day a week access to genetic services. We partner with health systems, genetic testing laboratories and biopharmaceutical companies. We accelerate, grow and provide service to their patients by launching genetics programs from the ground up, improving the scale and efficiency of existing genomic medicine programs, and providing genetic expertise and services to support clinical trials and sponsored genetic testing programs. With the largest national network of telehealth genetic counselors – averaging 10 years clinical experience – We have delivered more than 200,000 genetic counseling encounters, scaling to more than 8,500 patients per month and helping health systems expand network reach to more patients by delivering genetic care to patients anywhere, seven days a week. We are a covered benefit for 130 million people in the U.S. Through our nationwide virtual care delivery model, we provide genetics care to patients when and where it is most convenient, reducing patient wait times from as much as 18 months to one week. We have an extensive team of clinicians, including medical geneticists, genetic counselors, physicians and pharmacists. Our clinical specialties include oncology, reproductive health, cardiology, pediatrics, rare disease and proactive health.

Process, analyze, and annotate genomics and biomedical data at scale using containerized workflows.

Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate which is in Phase I/2 clinical study for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.

ImmunoMind is a UC Berkeley SkyDeck alumnus company, focused on understanding drug-human interactions to create more effective immunotherapies for underserved populations.

Enabling Nucleic Acid-Based Medicines to Treat Solid Tumor Cancers Ground-breaking Impilo Platform™ The Impilo Platform™ is designed to address key issues that have limited ability of emerging nucleic acid-based therapeutic modalities such as antisense, siRNA, tRNA, and mRNA and in vivo gene editing to effectively treat solid tumor cancers.

Inocras is a company for whole genome sequencing, providing a comprehensive view of a patient's entire genetic profile through WGS analysis and interpretation. Focusing on cancer and rare diseases, we aspire to fundamentally change how the world treats genetically driven diseases with an unsurpassed WGS databank and an integrated platform for generating, collecting, and analyzing genomic data.

InsightRX empowers life science and provider healthcare organizations to individualize treatment from clinical development to the point of care.

Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. We are adding to our talented team as we execute our commercial launch, advance our research and development efforts, and build our internal manufacturing capabilities. Iovance is headquartered in the San Francisco Bay Area. Our Iovance Cell Therapy Center (iCTC), a state-of-the-art manufacturing facility, is located in Philadelphia. We also have a research site in Tampa, Florida. Any information expressed by Iovance is subject to the risk factors and information on forward-looking statements contained in its filings with the Securities and Exchange Commission and available here: https://ir.iovance.com/sec-filings

Kardigan is a patient-driven heart health company that is modernizing cardiovascular drug development to deliver medicines that move patients beyond symptom management to functional cures. By matching critical disease drivers with treatment responders identified in clinical trials, Kardigan is developing a portfolio of medicines that modify the underlying cardiovascular disease pathophysiology to get patients closer to the cures they deserve.

At Kite, a Gilead Company, our singular focus is cell therapy to treat and potentially cure cancer. Our goal is to bring the promise of cell therapy to as many eligible patients as possible who may benefit. Since 2009, Kite has been at the forefront of cancer immunotherapy. Today, we are proud to be the leader in engineered T cell therapy for hematologic malignancies, but we recognize that this is just the beginning. Patients are at the heart of our focus on the cure, which is why we are committed to pursuing cell therapy as a transformative treatment option for as many people with cancer as possible who may benefit. Cancer is personal to us. Unlike traditional pharmaceutical manufacturing, our therapies are not created on an assembly line. Cell therapy specialists at our manufacturing facilities reengineer a patient’s own immune cells to attack and fight their cancer cells — one patient at a time. That sense of connection to the people we serve motivates us daily at Kite. Our corporate headquarters are located in Santa Monica, California, and we have dedicated cell therapy manufacturing facilities in California, Maryland and the Netherlands. If you’re passionate about changing the future of cancer treatment, let’s talk.

Lab Genomics, LLC (LG) is focused on delivering individualized medical care through molecular and genetic diagnostics.

MantleBio is building software to scale data driven discovery in biotech. It has become the norm for biotech companies to generate terabytes of data per day, but the majority of them lack the tools effectively utilize it. Through data management and analysis tools MantleBio provides an infrastructure for companies to make data driven decisions.

Mirador Therapeutics is a next-generation precision medicine company focused on immunology and inflammation. The company's Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to accelerate the next generation of precision medicines for immune-mediated diseases.

MiraDX was founded by Joanne Weidhaas, M.D., Ph.D. and Frank Slack, Ph.D., whose cutting-edge genetic research has unveiled a new class of genetic biomarkers, based on microRNA biology. Our mission is to apply these novel biomarkers to improve personalized cancer treatment. We have been applying these biomarkers to better direct cancer treatments, including radiation, chemotherapy, and newly developing immune therapies. We are able to apply our biomarkers to the daunting problem of toxicity from treatment, which no other set of biomarkers has been able to do. Through worldwide collaborations MiraDX has advanced this class of biomarkers to the forefront of personalized therapy, and has numerous collaborations across both academic and industry. We encourage you to learn more by visiting our website at MiraDX.com, as well as through visiting our sister non-profit, MiraKind, at MiraKind.org.

Monogram Biosciences, a LabCorp company, is a leader in developing and commercializing innovative products to help guide and improve the treatment of infectious diseases, cancer and other serious diseases. Our molecular diagnostics and testing services enable Healthcare providers to optimize treatment regimens for their patients to lead to better outcomes and reduced costs by matching the underlying molecular elements of an individual patient's disease to the drug best able to affect those elements. Further, we work with pharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics more efficiently by providing enhanced patient selection and monitoring capabilities throughout the development process. We have developed HIV tests, or assays, to help make the complexities of antiretroviral therapy easier to manage. We have also developed oncology products to help accelerate the development of targeted cancer therapeutics.

MutantDxidentifies DNA mutations in blood thatdiagnose cancer early enough to bepotentially curable.

At MyOme, we help families understand their DNA, and how it impacts their health throughout their lives, with secure and portable data using the latest technologies. We are always interested to hear from smart, passionate people with a background in bio stats, data science, and ML. Connect with us!

Neuron23™ Inc. is a leading clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The Company’s focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Founded in 2018, Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, CA.

Newomics is a biotech company that sells and develops innovative and integrative platforms for LC-MS. In particular, the award-winning multinozzle M3 emitter, with the MnESI ion source, enhances the ionization efficiency to achieve unprecedented sensitivity, throughput, and robustness. Our proprietary technology is based on silicon-microfluidic-chip for liquid chromatography-mass spectrometry (LC-MS), and offers unprecedented robustness, sensitivity, specificity, and throughput for analyzing molecules from minute amounts of biospecimens such as blood and urine. Our core technologies are built upon the multinozzle emitter array (MEA) technology, invented from the Lawrence Berkeley National Laboratory (Berkeley Lab), which has won the 2012 R&D 100 award.

Nexus Dx is a global provider of Near Patient Testing systems and advanced diagnostic solutions. The company is improving patient care by providing the medical community with rapid and reliable information at the point of care (POC), delivering patient information when and where it is needed most. Company Highlights: Primary focus on expansion of assay systems in the Near Patient Testing industry Multi-product revenue generating business Proprietary technologies and content Highly experienced management team Nexus Dx Inc.

Noetik is an AI-native biotechnology company. By harnessing the potential of self-supervised learning and human multimodal data, Noetik aims to discover better precision immunotherapies.

NVIGEN is a nanobiotechnology company that specializes in multifunctional nanoparticles for biomedical applications through their proprietary NID platform.

Octave® Bioscience Inc. is a commercial stage precision-medicine company delivering a new paradigm of care for Multiple Sclerosis and other neurodegenerative diseases. Octave’s Precision Care Solution is the industry’s first set of measurement tools that accurately and objectively measure disease activity, progression, and severity, allowing for better management of complex and high-cost neurodegenerative diseases, starting with Multiple Sclerosis and expanding into Parkinson’s disease. The Octave Solution includes the Octave MSDA Test, the first and only multivariate blood test for Multiple Sclerosis, that measures disease activity, enhanced MRI analytics and protocols, and a clinical care program that tracks and connects patients with MS certified nurse care partners in real time. By combining and analyzing multiple biological and contextual layers of data, delivering longitudinal and holistic perspectives of each patient, and revealing insights at population levels, the Octave Solution addresses unmet needs across the entire ecosystem of care, from patients and providers to pharma and payers. Octave is currently collaborating with leading clinics, payers, and pharma companies across the country.

Our goal is to find innovative therapies that address significant unmet medical needs for patients with inflammatory, rare and specialty diseases, and cancer. Notice to recruiters All recruitment vendors (temporary staffing agencies, placement services, and professional recruiters) are prohibited from contacting our employees. In order to be an authorized vendor partner for Peak Bio, all such organizations must have a formal written agreement with Peak Bio’s Human Resources Department.  Notice to Recruiters; Peak Bio’s receipt or acceptance of an unsolicited resume submitted by vendor organization does not constitute an actual or implied contract between Peak Bio and such organization. Peak Bio will not pay a fee to any vendor that does not have such agreement in place.

Q uses a systems biology approach called panomics to build a comprehensive, quantitative snapshot of your health by combining advanced non-invasive imaging, chemistry, genetics, vitals and your medical history.

QuickBiology is a fully automated, high-throughput genomic center equipped with all major next generation sequencing. QB provides state-of-the-art genomics technologies, comprehensive services, specialized expertise enabling these services in a cost-effective and timely manner to serve basic science and translational/clinical research. QB’s service included, but not limited to, RNA sequencing, whole exome sequencing, whole genome sequencing, ATAC sequencing and single cell RNA sequencing.

Real Time Genomics develops analytical solutions that reduce the cost and complexity of extracting knowledge from raw genomic data. We deliver validated, accurate results that are redefining personalized medicine. ___________________________________________________________________________________ At Real Time Genomics, we have a passion for genomics. Our core competence is a commitment to know, anticipate and deliver to the needs of leading biological researchers. The company has deep computational expertise in algorithms, coupled with extensive product development capabilities and a seasoned commercial team with over 100 years of success in bringing genomics' innovation to the life sciences industry. Today,we offer solutions for genomic analysis to practitioners of next generation sequencing (NGS) technologies. These solutions include complete analytical platforms for genomics and metagenomics. We can install these platforms to your compute environment or provide you access to them through cloud computing.

The last decade has seen amazing progress in neuroscience, enabling researchers to envision a new generation of brain machine interfaces. These systems will be used to treat chronic diseases like Parkinson's, epilepsy, and Alzheimer's. They will restore mobility to the paralyzed and speed recovery from a stroke. They may even allow us to control our mood and enhance our cognition. Rune Labs wants to build the software at the heart of these systems, and help accelerate the next wave of neuromodulation applications.

Santa Ana Bio is a precision immunology company leveraging multi-omics platforms and antibody engineering to deliver targeted therapies to patients with autoimmune and inflammatory diseases.

Free, unlimited storage with analytic tools to save you time. DNA app market place.

A pioneering, proven approach to antibody discovery that delivers actionable leads by capturing all available data.

The microbiome is the new frontier gut health and changes to your microbiome signature is now being understood as a central conduit of health and disease. IBD, IBS, Crohn's, colitis, type I diabetes, arthritis, metabolic syndrome, and several autoimmune disorders have all been associated with microbiome changes also known as dysbiosis. When you total the number of individuals affected by these diseases, over 80% Americans suffer from dysbiosis annually. With this much science there still aren't real solutions for dysbiosis. And since dysbiosis is the result of changes to the 1000's different microbes of our gut it is nearly impossible to find the right remedy for your specific dysbiosis. Sun Genomics is empowering the consumer to educate themselves about their microbiome signature and make informed, as well as transparent, product selections to manage their dysbiosis. We are helping consumers realize the power of their microbiota through genomics, probiotics, microbiology, informatics, and software.

Telesis Bio is empowering researchers to accelerate the creation of novel synthetic biology solutions to address some of humanity's greatest challenges. With our breakthrough automation solutions for biological synthesis and expertise in DNA biology, we enable rapid, accurate, and reproducible writing of DNA and mRNA for wide-ranging biological applications. Around the world, innovators are leveraging Telesis Bio's technology to overcome current bottlenecks in synthetic biology workflows and advance the discovery of cutting-edge solutions for health and technology. We are proud of our growing collaborations with partners that include premier academic research institutions, emerging start-ups to nearly all of the Top 25 Biopharma companies. Telesis Bio is honored to play a part in several pioneering advances of our customers and collaborators ranging from novel infectious disease vaccines, precision immunotherapy for cancer and antibody therapeutics to creation of engineered meat substitutes and sustainable cellular agricultural products.

Tradewind is dedicated to creating therapeutics for the most aggressive, difficult to treat cancers. Our lead program is a high-affinity, multifaceted attack antibody for cancer that functions through the inhibition of a novel, but validated, target protein. Tradewind’s first-in-class lead program operates through multiple modes of action - directly on cancer cells, and through the immune system, with both mechanisms of attack substantiated by in vivo studies. We can target the primary cancer, metastatic tumors, and even stop metastasis from spreading further. Our mission is to develop only transformative medicines that will have a significant impact on patient outcomes. Tradewind’s drug development is paired with a focus on biomarker identification, ensuring that our therapeutics will benefit the patients for whom it is most meaningful. The lead program is expected to be a game-changer for ovarian cancer, followed by other indications. Tradewind is backed by Y Combinator and the National Cancer Institute (NCI) to advance its innovative approach to fighting cancer.

Xpan is Developing the Next Generation of Minimally Invasive Surgical Access Ports